<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00642798</url>
  </required_header>
  <id_info>
    <org_study_id>0431-108</org_study_id>
    <secondary_id>2008_002</secondary_id>
    <nct_id>NCT00642798</nct_id>
  </id_info>
  <brief_title>An Open-Label, Single- &amp; Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects (0431-108)(COMPLETED)</brief_title>
  <official_title>An Open-Label, Single- &amp; Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      To support the registration of sitagliptin 100mg in china.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of sitagliptin after administration of single and multiple 100-mg doses of sitagliptin to healthy chinese adult subjects.</measure>
    <time_frame>Duration of Trial</time_frame>
  </primary_outcome>
  <enrollment type="Actual">16</enrollment>
  <condition>Diabetes Mellitus Non-insulin-dependent</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin phosphate</intervention_name>
    <description>Sitagliptin 100mg once daily on Day 1 for single dose, and once daily on Day4-9 for multiple dose.</description>
    <other_name>Januviaâ„¢</other_name>
    <other_name>MK0431</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject Has Been A Nonsmoker And/Or Has Not Used Nicotine Or Nicotine-Containing
             Products For At Least Approximately 6 Months; Subjects Who Have Discontinued Smoking
             Or The Use Of Nicotine/Nicotine Containing Products For At Least Approximately 3
             Months May Be Enrolled In The Study At The Discretion Of The Investigator

          -  Subject Has No Clinically Significant Abnormality On Electrocardiogram (Ecg) Performed
             At The Prestudy (Screening) Visit And/Or Prior To Administration Of The Initial Dose
             Of Study Drug

          -  Subject Is Judged To Be In Good Health Based On Medical History, Physical Examination,
             Vital Sign Measurements, And Laboratory Safety Tests Performed At The Prestudy
             (Screening) Visit And/Or Prior To Administration Of The Initial Dose Of Study Drug

          -  Subject Is Male Or Female 18 To 45 Years Of Age At The Prestudy (Screening) Visit.
             Female Subjects Of Reproductive Potential Must Demonstrate A Serum Beta-Hcg Level
             Consistent With The Nongravid State At The Prestudy (Screening) Visit And Agree To Use
             (And/Or Have Their Partner Use) Two Acceptable Methods Of Birth Control Beginning At
             Least 2 Weeks Prior To Administration Of The First Dose Of Study Drug, Throughout The
             Study (Including Washout Intervals Between Treatment Periods/Panels) And Until At
             Least 2 Weeks After Administration Of The Last Dose Of Study Drug In The Last
             Treatment Period. Acceptable Methods Of Birth Control Are: Abstinence, Intrauterine
             Device (Iud), Diaphragm, Spermicides, Cervical Cap, Contraceptive Sponge, And Condoms

          -  Subject Is Of Chinese Descent With All 4 Biological Grandparents Born In China And Of
             Chinese Descent

          -  Subject Is Willing To Comply With The Study Restrictions

          -  Subject Understands The Study Procedures And Agrees To Participate In The Study By
             Giving Written Informed Consent

          -  The Subject Has A Body Mass Index (BMI) Between 19 And 24 Kg/M2 And The Body Weight Is
             More Than 50 Kg At The Prestudy (Screening) Visit.

        Exclusion Criteria:

          -  Subject Consumes Excessive Amounts Of Alcohol, Defined As Greater Than 3 Glasses Of
             Alcoholic Beverages (1 Glass Is Approximately Equivalent To: Beer [284 Ml/10
             Ounces],Wine [125 Ml/4 Ounces], Or Distilled Spirits [25 Ml/1 Ounce]) Per Day.
             Subjects That Consume 4 Glasses Of Alcoholic Beverages Per Day May Be Enrolled At The
             Discretion Of The Investigator

          -  Subject Consumes Excessive Amounts, Defined As Greater Than 6 Servings (1 Serving Is
             Approximately Equivalent To 120 Mg Of Caffeine) Of Coffee, Tea, Cola, Or Other
             Caffeinated Beverages Per Day

          -  Subject Has A History Of Any Illness That, In The Opinion Of The Study Investigator,
             Might Confound The Results Of The Study Or Poses An Additional Risk To The Subject By
             Their Participation In The Study

          -  Subject Has A History Of Neoplastic Disease.

          -  Subject Has A History Of Significant Multiple And/Or Severe Allergies, Or Has Had An
             Anaphylactic Reaction Or Significant Intolerability To Prescription Or
             Non-Prescription Drugs Or Food

          -  Subject Has A History Of Stroke, Chronic Seizures, Or Major Neurological Disorder

          -  Subject Has An Estimated Creatinine Clearance Of &lt;=80 Ml/Min Based On The
             Cockcroft-Gault Equation

          -  Subject Has Had Major Surgery, Donated Or Lost 1 Unit Of Blood (Approximately 500 Ml)
             Or Participated In Another Investigational Study Within 4 Weeks Prior To The Prestudy
             (Screening) Visit

          -  Subject Is A Nursing Mother

          -  Subject Is Currently A Regular User (Including Recreational Use)Of Any Illicit Drugs
             Or Has A History Of Drug (Including Alcohol) Abuse Within Approximately 6 Months

          -  Subject Is Mentally Or Legally Incapacitated, Has Significant Emotional Problems At
             The Time Of Prestudy (Screening) Visit Or Expected During The Conduct Of The Study Or
             Has A History Of A Clinically Significant Psychiatric Disorder Over The Last 5 To 10
             Years.Subjects Who Have Had Situational Depression May Be Enrolled In The Study At The
             Discretion Of The Investigator

          -  Subject Is Unable To Refrain From Or Anticipates The Use Of Any Medication, Including
             Prescription And Non-Prescription Drugs Or Herbal Remedies (Such As St. John
             Wort[Hypericum Perforatum]) Beginning Approximately 2 Weeks (Or 5 Half-Lives) Prior To
             Administration Of The Initial Dose Of Study Drug, Throughout The Study (Including
             Washout Intervals Between Treatment Periods), Until The Post-study Visit

          -  Subject Is Under The Age Of Legal Consent

          -  There Is Any Concern By The Investigator Regarding The Safe Participation Of The
             Subject In The Study Or For Any Other Reason, The Investigator Considers The Subject
             Inappropriate For Participation In The Study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>(MedWatch - FDA maintained medical product safety Information)</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>(Merck: Patient &amp; Caregiver U.S. Product Web Site)</description>
  </link>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2008</study_first_submitted>
  <study_first_submitted_qc>March 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2008</study_first_posted>
  <last_update_submitted>February 2, 2015</last_update_submitted>
  <last_update_submitted_qc>February 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

